Scarica l'app Stockscreener
9.14
1.40%
-0.13
Dopo l'orario di chiusura:
9.00
-0.14
-1.53%
Precedente Chiudi:
$9.27
Aprire:
$9.26
Volume 24 ore:
3.56M
Relative Volume:
1.48
Capitalizzazione di mercato:
$1.48B
Reddito:
$181.41M
Utile/perdita netta:
$-59.56M
Rapporto P/E:
-21.76
EPS:
-0.42
Flusso di cassa netto:
$-38.83M
1 W Prestazione:
+11.60%
1M Prestazione:
+22.36%
6M Prestazione:
+124.02%
1 anno Prestazione:
+200.66%
Intervallo 1D:
$9.02
$9.40
Intervallo di 1 settimana:
$7.775
$9.40
Portata 52W:
$2.82
$9.40
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
Nome
Xeris Biopharma Holdings Inc
Settore
Industria
Telefono
844-445-5704
Indirizzo
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
Confronta XERS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XERS
Xeris Biopharma Holdings Inc
|
9.14 | 1.31B | 181.41M | -59.56M | -38.83M | -0.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-12 | Ripresa | H.C. Wainwright | Buy |
| 2024-11-11 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-03-28 | Iniziato | Oppenheimer | Outperform |
| 2023-08-28 | Iniziato | Craig Hallum | Buy |
| 2022-10-21 | Iniziato | Jefferies | Buy |
| 2022-04-28 | Iniziato | Craig Hallum | Buy |
| 2021-11-17 | Iniziato | SVB Leerink | Outperform |
| 2021-10-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2020-02-18 | Iniziato | Piper Sandler | Overweight |
| 2018-07-16 | Iniziato | Jefferies | Buy |
| 2018-07-16 | Iniziato | Leerink Partners | Outperform |
| 2018-07-16 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Xeris Biopharma Holdings Inc Borsa (XERS) Ultime notizie
Quantitative breakdown of Xeris Biopharma Holdings Inc. recent moveInflation Watch & Reliable Intraday Trade Plans - newser.com
Xeris Biopharma (XERS) Surges 14.2%: Is This an Indication of Further Gains? - Yahoo Finance
Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) High Institutional Ownership Speaks for Itself as Stock Continues to Impress, up 13% Over Last Week - 富途牛牛
XERS Crosses Above Average Analyst Target - Nasdaq
There's Reason For Concern Over Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Massive 26% Price Jump - simplywall.st
Xeris Biopharma (NASDAQ:XERS) Sets New 52-Week HighTime to Buy? - MarketBeat
Xeris Biopharma Holdings Inc. stock momentum explainedEarnings Performance Report & Free AI Powered Buy and Sell Recommendations - newser.com
Xeris Biopharma (NASDAQ:XERS) Upgraded to Strong-Buy at Zacks Research - MarketBeat
Can machine learning forecast Xeris Biopharma Holdings Inc. recoveryInsider Buying & Technical Entry and Exit Tips - newser.com
Why Xeris Biopharma Holdings Inc. (2B30) stock could outperform next yearJuly 2025 Breakouts & AI Powered Market Trend Analysis - newser.com
Why Xeris Biopharma Holdings Inc. (2B30) stock could be top winnerEarnings Beat & Safe Entry Zone Identification - newser.com
Can Xeris Biopharma Holdings Inc. stock weather global recessionLayoff News & Community Verified Watchlist Alerts - newser.com
When is the best time to exit Xeris Biopharma Holdings Inc.Weekly Trade Recap & Accurate Trade Setup Notifications - newser.com
Xeris Biopharma Holdings Inc. stock prediction for this weekDay Trade & Weekly Top Stock Performers List - newser.com
Beat the Market the Zacks Way: MariMed, Xeris Biopharma, Lam Research in Focus - Yahoo Finance
How to read the order book for Xeris Biopharma Holdings Inc.Bear Alert & Safe Entry Point Identification - newser.com
Risk vs reward if holding onto Xeris Biopharma Holdings Inc.2025 Top Decliners & Reliable Entry Point Alerts - newser.com
Can Xeris Biopharma Holdings Inc. recover in the next quarter2025 Valuation Update & Reliable Momentum Entry Alerts - newser.com
Volume spikes in Xeris Biopharma Holdings Inc. stock – what they meanJuly 2025 Macro Moves & Capital Efficiency Focused Ideas - newser.com
What is the fair value estimate for Xeris Biopharma Holdings Inc. (2B30) stock in 2025Weekly Market Summary & Free Safe Entry Trade Signal Reports - newser.com
Analyzing net buyer seller activity in Xeris Biopharma Holdings Inc.IPO Watch & Reliable Intraday Trade Plans - newser.com
Is it time to cut losses on Xeris Biopharma Holdings Inc.2025 Key Highlights & Community Verified Trade Alerts - newser.com
Measuring Xeris Biopharma Holdings Inc.’s beta against major indicesTrade Risk Summary & Free Growth Oriented Trading Recommendations - newser.com
How buyback programs support Xeris Biopharma Holdings Inc. (2B30) stock2025 AllTime Highs & Low Risk Growth Stock Ideas - newser.com
Weiss Ratings Reiterates Sell (D-) Rating for Xeris Biopharma (NASDAQ:XERS) - MarketBeat
Xeris Biopharma (NASDAQ:XERS) Stock Price Down 4%Here's What Happened - MarketBeat
Xeris Biopharma Holdings (XERS): Exploring Valuation as Analysts Grow Bullish on Breakeven Prospects and Earnings Progress - simplywall.st
Xeris Biopharma Reaches New 52-Week High of $8.51, Up 253% - Markets Mojo
News impact scoring models applied to Xeris Biopharma Holdings Inc.Portfolio Value Summary & Growth Focused Stock Pick Reports - newser.com
Xeris Biopharma Holdings Inc.’s volatility index tracking explainedMarket Risk Analysis & Low Risk Investment Opportunities - newser.com
Will Xeris Biopharma Holdings Inc. outperform the marketJuly 2025 Big Picture & AI Enhanced Trading Alerts - newser.com
Will Xeris Biopharma Holdings Inc. stock deliver shareholder valueJuly 2025 Market Mood & Low Drawdown Momentum Ideas - newser.com
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635c4 - MarketScreener
XERS Back In The Spotlight As Recorlev Surges, Gvoke Steadies, And Keveyis Holds Strong - RTTNews
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Xeris Biopharma's Path Toward Profitability Might Change The Case For Investing In XERS - simplywall.st
Xeris Biopharma (XERS) is a Great Momentum Stock: Should You Buy? - sharewise.com
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS): Are Analysts Optimistic? - Yahoo Finance
Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
Why Xeris Biopharma Holdings Inc. stock could be next big winnerQuarterly Earnings Summary & Detailed Earnings Play Strategies - newser.com
Xeris Biopharma Holdings Inc Azioni (XERS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):